NasdaqGS:APLSBiotechs
A Look At Apellis Pharmaceuticals (APLS) Valuation After Its Sharp Recent Share Price Surge
Apellis Pharmaceuticals (APLS) has drawn fresh attention after recent share price moves, prompting investors to reassess how its current valuation compares with its commercial portfolio in rare disease and eye care treatments.
See our latest analysis for Apellis Pharmaceuticals.
The recent one day share price return of 135.40% and 7 day share price return of 133.49% have shifted sentiment sharply. However, the 3 year total shareholder return of a 48.45% decline and 5 year total shareholder...